U.S. markets closed

Pfizer Inc. (PFE)

NYSE - NYSE Delayed Price. Currency in USD
28.78+0.15 (+0.52%)
At close: 04:00PM EST
28.76 -0.02 (-0.07%)
After hours: 05:04PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Triple Moving Average Crossover

Triple Moving Average Crossover

Previous Close28.63
Bid28.76 x 2900
Ask28.77 x 4000
Day's Range28.59 - 28.97
52 Week Range28.30 - 54.93
Avg. Volume31,396,747
Market Cap162.504B
Beta (5Y Monthly)0.56
PE Ratio (TTM)15.73
EPS (TTM)1.83
Earnings DateJan 29, 2024 - Feb 02, 2024
Forward Dividend & Yield1.64 (5.73%)
Ex-Dividend DateNov 09, 2023
1y Target Est40.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
8% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for PFE

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Pfizer, Inc.
    Analyst Report: Pfizer Inc.Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor.
    Fair Value
    Economic Moat
    7 days agoMorningstar
View more
  • Motley Fool

    Pfizer's Latest Ozempic Competitor Just Flopped (Again). Is the Stock Still a Buy?

    On Dec. 1, Pfizer (NYSE: PFE) reported some less-than-great news to investors. In short, its latest attempt at developing a drug to compete with Novo Nordisk's blockbuster medicine Ozempic will not be advancing into late-stage clinical trials. Now, the company's bid to capture portions of the extremely lucrative type 2 diabetes and obesity drug markets looks like it's in trouble.

  • Insider Monkey

    10 Cheap Dividend Stocks with High Yields

    In this article, we discuss 10 cheap dividend stocks with high yields. You can skip our detailed analysis of dividend stocks and their performance in the past, and go directly to read 5 Cheap Dividend Stocks with High Yields. In 2022, value stocks did better than growth stocks, marking the first time of value outperformance […]

  • Zacks

    Pharma Stock Roundup: ABBV to Buy CERE, JNJ's 2024 View, LLY & NVS Get FDA Nod

    AbbVie (ABBV) offers to acquire Cerevel Therapeutics for $8.7 billion. J&J (JNJ) announces sales and earnings growth expectations for 2024.